Ashwin N Ananthakrishnan1, Hai Yun Shi2, Whitney Tang2, Cindy C Y Law3, Joseph J Y Sung2, Francis K L Chan2, Siew C Ng2. 1. Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 2. Department of Medicine and Therapeutics, Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong. 3. University of Ottawa School of Medicine, Ottawa, ON, Canada.
Abstract
BACKGROUND: Little is known of the clinical outcome of patients with older-onset inflammatory bowel disease [IBD]. We performed a systematic review to determine phenotype and outcomes of older-onset IBD compared with younger-onset subjects. METHODS: A systematic search of Embase and Medline up to June 2015 identified studies investigating phenotype and outcomes of older-onset [diagnosed at age ≥ 50 years] Crohn's disease [CD] and ulcerative colitis [UC] subjects. Pooled analyses of disease phenotype, medication use, and disease-related surgery were calculated. RESULTS: We analysed findings from 43 studies comprising 8274 older-onset and 34641 younger-onset IBD subjects. Compared with younger-onset patients, older-onset CD patients were more likely to have colonic disease (odds ratio [OR] 2.56, 95% confidence interval [CI] 1.88 - 3.48) and inflammatory behaviour [OR 1.19, 95% CI 1.07 - 1.33], and less likely to have penetrating disease or perianal involvement. More older-onset UC patients had left-sided colitis [OR 1.49, 95% CI 1.18 - 1.88]. Although fewer older-onset IBD patients received immunomodulators [CD: OR 0.44; UC: OR 0.60] or biologicals [CD: OR 0.34; UC: OR 0.41], older-onset CD was similar in the need for surgery [OR 0.70, 95% CI 0.40 - 1.22] whereas more older-onset UC patients underwent surgery [OR 1.36, 95% CI 1.18 - 1.57]. CONCLUSIONS: Elderly IBD patients present with less complicated disease, but have similar or higher rates of surgery than non-elderly patients. Whether this reflects a non-benign disease course, physicians' reluctance to employ immunomodulators, or both, merits further study which is essential for improving the care of IBD in the elderly.
BACKGROUND: Little is known of the clinical outcome of patients with older-onset inflammatory bowel disease [IBD]. We performed a systematic review to determine phenotype and outcomes of older-onset IBD compared with younger-onset subjects. METHODS: A systematic search of Embase and Medline up to June 2015 identified studies investigating phenotype and outcomes of older-onset [diagnosed at age ≥ 50 years] Crohn's disease [CD] and ulcerative colitis [UC] subjects. Pooled analyses of disease phenotype, medication use, and disease-related surgery were calculated. RESULTS: We analysed findings from 43 studies comprising 8274 older-onset and 34641 younger-onset IBD subjects. Compared with younger-onset patients, older-onset CD patients were more likely to have colonic disease (odds ratio [OR] 2.56, 95% confidence interval [CI] 1.88 - 3.48) and inflammatory behaviour [OR 1.19, 95% CI 1.07 - 1.33], and less likely to have penetrating disease or perianal involvement. More older-onset UC patients had left-sided colitis [OR 1.49, 95% CI 1.18 - 1.88]. Although fewer older-onset IBD patients received immunomodulators [CD: OR 0.44; UC: OR 0.60] or biologicals [CD: OR 0.34; UC: OR 0.41], older-onset CD was similar in the need for surgery [OR 0.70, 95% CI 0.40 - 1.22] whereas more older-onset UC patients underwent surgery [OR 1.36, 95% CI 1.18 - 1.57]. CONCLUSIONS: Elderly IBD patients present with less complicated disease, but have similar or higher rates of surgery than non-elderly patients. Whether this reflects a non-benign disease course, physicians' reluctance to employ immunomodulators, or both, merits further study which is essential for improving the care of IBD in the elderly.
Authors: Shanika de Silva; Christopher Ma; Marie-Claude Proulx; Marcelo Crespin; Belle S Kaplan; James Hubbard; Martin Prusinkiewicz; Andrew Fong; Remo Panaccione; Subrata Ghosh; Paul L Beck; Anthony Maclean; Donald Buie; Gilaad G Kaplan Journal: Clin Gastroenterol Hepatol Date: 2011-07-30 Impact factor: 11.382
Authors: Meenakshi Bewtra; Craig W Newcomb; Qufei Wu; Lang Chen; Fenglong Xie; Jason A Roy; Cary B Aarons; Mark T Osterman; Kimberly A Forde; Jeffrey R Curtis; James D Lewis Journal: Ann Intern Med Date: 2015-08-18 Impact factor: 25.391
Authors: R K Weersma; P C F Stokkers; A A van Bodegraven; R A van Hogezand; H W Verspaget; D J de Jong; C J van der Woude; B Oldenburg; R K Linskens; E A M Festen; G van der Steege; D W Hommes; J B A Crusius; C Wijmenga; I M Nolte; G Dijkstra Journal: Gut Date: 2008-09-29 Impact factor: 23.059
Authors: David J Cutler; Michael E Zwick; David T Okou; Sampath Prahalad; Thomas Walters; Stephen L Guthery; Marla Dubinsky; Robert Baldassano; Wallace V Crandall; Joel Rosh; James Markowitz; Michael Stephens; Richard Kellermayer; Marian Pfefferkorn; Melvin B Heyman; Neal LeLeiko; David Mack; Dedrick Moulton; Michael D Kappelman; Archana Kumar; Jarod Prince; Promita Bose; Kajari Mondal; Dhanya Ramachandran; John F Bohnsack; Anne M Griffiths; Yael Haberman; Jonah Essers; Susan D Thompson; Bruce Aronow; David J Keljo; Jeffrey S Hyams; Lee A Denson; Subra Kugathasan Journal: PLoS One Date: 2015-06-22 Impact factor: 3.240
Authors: Tomer Adar; David Faleck; Saranya Sasidharan; Kelly Cushing; Nienke Z Borren; Niharika Nalagatla; Ryan Ungaro; Wayne Sy; Samuel C Owen; Anish Patel; Benjamin L Cohen; Ashwin N Ananthakrishnan Journal: Aliment Pharmacol Ther Date: 2019-02-17 Impact factor: 8.171
Authors: Siddharth Singh; Larry W Stitt; Guangyong Zou; Reena Khanna; Parambir S Dulai; William J Sandborn; Brian G Feagan; Vipul Jairath Journal: Aliment Pharmacol Ther Date: 2019-03-19 Impact factor: 8.171